[…]
Rituximab Receives FDA Approval for Treatment of RA
[…]
Sleep Disturbance is Increased in Rheumatoid Arthritis
[…]
Subcutaneous vs. Oral Methotrexate : Which is Preferred in Rheumatoid Arthritis?
Oral vs. subcutaneous (sq) administration of methotrexate is generally considered equivalent in rheumatoid arthritis (RA) treatment. However, the enhanced bioavailability of sq methotrexate may make this route of administration preferable to the oral route in certain patients.
Risedronate not an Effective Disease Modifier in Knee Osteoarthritis
Despite its prevalence, no effective pharmacotherapies have been definitively proven to modify the course of radiographic knee osteoarthritis (OA). Risedronate, a bisphosphonate that reduces bone turnover, has been shown in animal models to inhibit cartilage degradation and progression of disease.
ASSURE Trial Explores the Safety of Abatacept Therapy in RA
Safety data obtained from randomized clinical trials designed to evaluate the efficacy of rheumatoid arthritis (RA) drugs can be misleading for several reasons. Often, the studies are short term (6 months or less), and are highly selective of the subjects included (usually subjects with very active disease and with few medical comorbidities). In addition, background DMARDs are usually restricted to methotrexate.
